In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer
Upon determination of eligibility, all patients will be receive: * Topotecan
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Overall response rate
Median survival
1-year survival
Symptomatic improvement
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.